A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

• Published in: JACC. Basic to translational science Vol. 1; no. 7; pp. 576 - 586
• Main Authors: Lenihan, Daniel J., MD, Anderson, Sarah A., ACNP, Lenneman, Carrie Geisberg, MD, Brittain, Evan, MD, MSCI, Muldowney, James A.S., MD, Mendes, Lisa, MD, Zhao, Ping Z., PhD, Iaci, Jennifer, MS, Frohwein, Stephen, MD, Zolty, Ronald, MD, PhD, Eisen, Andrew, MD, PhD, Sawyer, Douglas B., MD, PhD, Caggiano, Anthony O., MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2016; Elsevier
• Subjects: cardiac repair; Cardiovascular; CLINICAL RESEARCH; growth factor; neuregulin; systolic dysfunction; NYHA; heart failure; NRG; cardiac repair; AE; GGF; treatment-emergent adverse event; neuregulin; LVEF; adverse event; systolic dysfunction; area under the curve; DLT; left ventricular ejection fraction; AUC; left ventricular systolic dysfunction; growth factor; TEAE; New York Heart Association functional class; dose-limiting toxicity; LVSD; glial growth factor; HF; LVEF, left ventricular ejection fraction; AUC, area under the curve; GGF, glial growth factor; LVSD, left ventricular systolic dysfunction; DLT, dose-limiting toxicity; AE, adverse event; HF, heart failure; NYHA, New York Heart Association functional class; TEAE, treatment-emergent adverse event; NRG, neuregulin
• ISSN: 2452-302X; 2452-302X
• DOI: 10.1016/j.jacbts.2016.09.005

Visual Abstract